FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022672351> ?p ?o ?g. }

• W2022672351 endingPage "1345.e1" @default.
• W2022672351 startingPage "1337" @default.
• W2022672351 abstract "The clinical impact of nonadherence to gastroprotective agents (GPAs) coprescribed with anti-inflammatory therapies has not been evaluated. In a large, commercial, managed-care database, we retrospectively characterized the use of GPAs among patients receiving nonselective nonsteroidal anti-inflammatory drugs (ns-NSAIDs) or cyclooxygenase-2-selective inhibitors (coxibs) and determined the impact of nonadherence on the likelihood of gastroduodenal ulcer complications.Analyses identified the populations of patients with concomitant histamine-2 receptor antagonist or proton pump inhibitor (PPI) therapy and determined adherence with the prescribed therapy with respect to the duration of anti-inflammatory treatment. Multivariate regression analyses modeled the association between adherence with concomitant protective therapy and the likelihood of upper gastrointestinal (GI) complications including peptic ulcer disease, ulcer, and/or upper-GI bleed.Among 144,203 patients newly prescribed anti-inflammatory therapies, 1.8% received concomitant GPA treatment (ns-NSAIDs, 1.4% vs coxibs, 2.6%; P < .0001). The likelihood of GPA use increased with the presence of risk factors: age older than 65 years (odds ratio [OR], 1.40; 95% confidence interval [CI], 1.3-1.5) and prior history of peptic ulcer disease (OR, 2.5; 95% CI, 1.8-3.3), esophagitis/gastroesophageal reflux (OR, 3.8; 95% CI, 3.5-4.1), ulcer/upper-GI bleed (OR, 1.4; 95% CI, 1.2-1.5), or gastritis (OR, 2.5; 95% CI, 2.2-2.8). Of patients receiving concomitant PPI therapy, 68% had adherence rates of 80% or more. A significantly higher risk of upper-GI ulcers/complications was observed in ns-NSAID patients with adherence rates of less than 80% compared with adherence rates of 80% or more (OR, 2.4; 95% CI, 1.0-5.6), but no such relationship was observed among patients who took coxibs.Few patients receive concomitant GPA therapy when prescribed anti-inflammatory treatment, although use increased with the presence of risk factors. Adherence to concomitant therapy is paramount to reducing GI events among ns-NSAID users and educational efforts should be undertaken to promote use of and adherence to GPA therapy among these patients." @default.
• W2022672351 created "2016-06-24" @default.
• W2022672351 creator A5004621550 @default.
• W2022672351 creator A5056324771 @default.
• W2022672351 creator A5058477882 @default.
• W2022672351 creator A5086368670 @default.
• W2022672351 creator A5091853765 @default.
• W2022672351 date "2006-11-01" @default.
• W2022672351 modified "2023-10-17" @default.
• W2022672351 title "Impact of Adherence to Concomitant Gastroprotective Therapy on Nonsteroidal-Related Gastroduodenal Ulcer Complications" @default.
• W2022672351 cites W10412033 @default.
• W2022672351 cites W1728920319 @default.
• W2022672351 cites W1967276177 @default.
• W2022672351 cites W1967858966 @default.
• W2022672351 cites W1972368489 @default.
• W2022672351 cites W1981816788 @default.
• W2022672351 cites W1998161037 @default.
• W2022672351 cites W2001350224 @default.
• W2022672351 cites W2004718890 @default.
• W2022672351 cites W2016008591 @default.
• W2022672351 cites W2021892954 @default.
• W2022672351 cites W2022630327 @default.
• W2022672351 cites W2024237851 @default.
• W2022672351 cites W2024352468 @default.
• W2022672351 cites W2028873410 @default.
• W2022672351 cites W2033766631 @default.
• W2022672351 cites W2034013987 @default.
• W2022672351 cites W2042353763 @default.
• W2022672351 cites W2043396343 @default.
• W2022672351 cites W2051691071 @default.
• W2022672351 cites W2057180612 @default.
• W2022672351 cites W2066836798 @default.
• W2022672351 cites W2077018765 @default.
• W2022672351 cites W2082999830 @default.
• W2022672351 cites W2083464592 @default.
• W2022672351 cites W2103688147 @default.
• W2022672351 cites W2104379105 @default.
• W2022672351 cites W2110739516 @default.
• W2022672351 cites W2123973590 @default.
• W2022672351 cites W2124451844 @default.
• W2022672351 cites W2155441883 @default.
• W2022672351 cites W2158880037 @default.
• W2022672351 cites W2163756514 @default.
• W2022672351 cites W2313437711 @default.
• W2022672351 cites W2330496155 @default.
• W2022672351 cites W2333044470 @default.
• W2022672351 cites W2339197236 @default.
• W2022672351 cites W2610860323 @default.
• W2022672351 cites W334564628 @default.
• W2022672351 cites W4235281521 @default.
• W2022672351 cites W4252390937 @default.
• W2022672351 cites W4361867558 @default.
• W2022672351 doi "https://doi.org/10.1016/j.cgh.2006.08.016" @default.
• W2022672351 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17088110" @default.
• W2022672351 hasPublicationYear "2006" @default.
• W2022672351 type Work @default.
• W2022672351 sameAs 2022672351 @default.
• W2022672351 citedByCount "87" @default.
• W2022672351 countsByYear W20226723512012 @default.
• W2022672351 countsByYear W20226723512013 @default.
• W2022672351 countsByYear W20226723512014 @default.
• W2022672351 countsByYear W20226723512015 @default.
• W2022672351 countsByYear W20226723512016 @default.
• W2022672351 countsByYear W20226723512018 @default.
• W2022672351 countsByYear W20226723512019 @default.
• W2022672351 countsByYear W20226723512022 @default.
• W2022672351 countsByYear W20226723512023 @default.
• W2022672351 crossrefType "journal-article" @default.
• W2022672351 hasAuthorship W2022672351A5004621550 @default.
• W2022672351 hasAuthorship W2022672351A5056324771 @default.
• W2022672351 hasAuthorship W2022672351A5058477882 @default.
• W2022672351 hasAuthorship W2022672351A5086368670 @default.
• W2022672351 hasAuthorship W2022672351A5091853765 @default.
• W2022672351 hasConcept C126322002 @default.
• W2022672351 hasConcept C141071460 @default.
• W2022672351 hasConcept C156957248 @default.
• W2022672351 hasConcept C2776246392 @default.
• W2022672351 hasConcept C2776259030 @default.
• W2022672351 hasConcept C2777498785 @default.
• W2022672351 hasConcept C2779134260 @default.
• W2022672351 hasConcept C2779384505 @default.
• W2022672351 hasConcept C2779920096 @default.
• W2022672351 hasConcept C2781025758 @default.
• W2022672351 hasConcept C2909576783 @default.
• W2022672351 hasConcept C43270747 @default.
• W2022672351 hasConcept C44249647 @default.
• W2022672351 hasConcept C71924100 @default.
• W2022672351 hasConcept C90924648 @default.
• W2022672351 hasConceptScore W2022672351C126322002 @default.
• W2022672351 hasConceptScore W2022672351C141071460 @default.
• W2022672351 hasConceptScore W2022672351C156957248 @default.
• W2022672351 hasConceptScore W2022672351C2776246392 @default.
• W2022672351 hasConceptScore W2022672351C2776259030 @default.
• W2022672351 hasConceptScore W2022672351C2777498785 @default.
• W2022672351 hasConceptScore W2022672351C2779134260 @default.
• W2022672351 hasConceptScore W2022672351C2779384505 @default.
• W2022672351 hasConceptScore W2022672351C2779920096 @default.
• W2022672351 hasConceptScore W2022672351C2781025758 @default.

• next